Day: October 20, 2025

Sampo plc, stock exchange release, 20 October 2025 at 8:30 am EEST Sampo plc’s share buybacks 17 October 2025                                                      On 17 October 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  5,272 9.58 AQEU    136,961 9.58 CEUX  44,905 9.59 TQEX  227,117 9.59 XHELTOTAL 414,255 9.59  * rounded to two decimals                      On 6 August 2025, Sampo announced a share buyback programme of up to a maximum of EUR 200 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation...

UAB “Orkela”, legal entity code 304099538, registered address Jogailos g. 4, Vilnius, Republic of Lithuania (hereinafter – the Issuer), whose securities (hereinafter – the Bonds) are included and traded on the Nasdaq bond list, and which are also publicly offered under the base prospectus approved by the Bank of Lithuania on 14 November 2023 (hereinafter – the Prospectus), hereby informs of the following: The Issuer has concluded a EUR 40 million credit agreement with AB SEB Bank for the refinancing of Bonds ISIN LT0000405961. This step is aimed at ensuring efficient refinancing of the existing bond obligations and maintaining the Issuer’s stable financial position. On behalf of the Issuer: Anastasija PocienėGeneral Manageranastasija.pociene@lordslb.lt

OSLO, Norway (20 October 2025) – TGS, a leading provider of energy data and intelligence, is pleased to announce the award of an OBN acquisition contract in Gulf of America. The 4D monitor survey is scheduled to commence in Q4 2025, and the acquisition duration is approximately 4.5 months. The contract was not included in the booked position disclosed in TGS’ Q2 2025 presentation. Kristian Johansen, CEO of TGS, commented, “The Gulf of America is a core market for our OBN business, and we are very pleased to secure this contract for a repeat IOC customer. The client values our OBN technology, and in combination with our proven track record of project execution and timely delivery, they are confident we will deliver high-quality data and insights to optimize production from one of their highest producing facilities in the Gulf of America.”...

Oslo, 20 October 2025: (OSE ticker: VOW) Preliminary unaudited consolidated accounts for Vow ASA (the “Group” or the “Company”) for Q3 2025 indicate a lower-than-expected EBITDA associated with two key projects in the Industrial segment.  The positive development in the Maritime and Aftersales segments continues, driven by strong demand, high activity, and increased margins. A thorough review of the two major industry projects has revealed that total costs to completion in 2026 have been underestimated. This impacts the project margins and technical reporting of the progress of costs, and leads to reversal of revenue in Q3 2025. The reversal of revenue has no cash impact.  The preliminary EBITDA for Q3 2025 shows approximately NOK -70 million for the Industrial Solutions segment, and a total EBITDA for the Group of approximately NOK -33...

FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as shown in phase II NOBILITY and phase III REGENCY data1,2 Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study2 Lupus nephritis affects more than 1.7 million people worldwide, predominantly women of colour and childbearing age, with up to one-third of patients progressing to end-stage kidney disease3-6Basel, 20 October 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro®(obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy, as well as a shorter 90-minute infusion time after the first infusion, for...

Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 13 October up to and including 17 October 2025 a total of 29.981 shares were repurchased at an average price of €16.6672 for a total amount of €499,698.04 To date, the total consideration for shares repurchased amounts to €5,024,854.16 representing 50.25% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the progress of the share buyback program on its website: https://www.corbion.com/Investor-relations/shareholder-information This overview contains detailed information on the daily amount of repurchased shares and individual share purchase transactions.Attachment2025 SBB weekly update 20251017

Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-doseCompared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a reduction in laboratory-confirmed influenza hospitalizations by an additional 31.9% (95% CI, 19.7 to 42.2; p

Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo1 IMvigor011 is the first global phase III study to read out pioneering a ctDNA- guided approach to post-surgery treatment in muscle-invasive bladder cancer Data being presented as part of the Presidential Symposium at the ESMO Congress 2025Basel, 20 October 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III IMvigor011 study evaluating Tecentriq® (atezolizumab) as an adjuvant treatment for people with muscle-invasive bladder cancer (MIBC) who are at risk of recurrence after surgery (cystectomy) and have detectable circulating tumour DNA (ctDNA). In this ctDNA-guided setting, Tecentriq reduced the risk of death (overall survival, OS) by 41% and the risk of disease recurrence...